DNA-MRD testing better predicted outcomes versus PET/CT scans for large B-cell lymphoma, leading to NCCN guideline updates ...

Research reveals innovative methods for detecting minimal residual disease in ovarian cancer, enhancing prognosis and paving ...

Although published studies now record levels MRD negativity to 10 -6 and even 10 -7, the agreed-upon standard for FDA is a threshold of 10 -5, which means a test must detect the presence of ...

If approved, Signatera could help physicians to monitor molecular markers of bladder cancer relapse, allowing them to ...

MRD Response with novel first-line therapy in high-risk DLBCL – Analysis of a Phase 1b trial CC-220-DLBCL-001 combining golcadomide with R-CHOP in previously untreated aggressive B-cell lymphoma ...

Minimal residual disease (MRD) has emerged as a significant marker in the treatment of multiple myeloma (MM), allowing clinicians to make more informed decisions about therapy. MRD testing helps ...

ctDNA MRD testing would reduce costs by 21% (1,068,040 vs. 846,356, a savings of $221,684 in total or $0.018 per member per month [PMPM]) for a commercial plan population and by 5% (2,550,029 vs ...

Emerging data suggest that isatuximab‐KRd and daratumumab‐KRd produce superior depth of response compared with KRd alone, with sustained MRD negativity and encouraging progression‐free survival in ...

Just after market close, Adaptive Biotechnologies (NASDAQ: ADPT) took the wraps off its second quarter. The following day, ...